Sotera Health Draws Mostly Positive Analyst Sentiment
Eleven brokerages covering Sotera Health have assigned a consensus Moderate Buy rating, with eight buy and three hold recommendations. The average 12-month price target is $21.50, above the stock's $18.45 opening, and the company beat quarterly expectations with EPS of $0.26 versus $0.24 and revenue of $321.38 million, up 9.2% year over year. Insiders sold about $24 million of stock over the past 90 days, while institutional ownership stands at 91.03%.
Analyst price targets vary widely, from UBS's $19 to Piper Sandler's $25, reflecting divergent views on the company's trajectory. Barclays and Goldman Sachs both adopted bullish stances, while JPMorgan remained cautious with a neutral rating and $18 target. The stock trades near its 52-week high of $19.85, with a beta of 1.77 indicating notable volatility relative to the broader market.
The company's financial profile shows a debt-to-equity ratio of 3.33 and a return on equity of 40.12%. Management guided FY 2026 EPS to a range of $0.95 to $1.01, while consensus sits at $0.86. Chairman Petras's August sale of 850,000 shares at $18.50 reduced his stake by 17.64%, though he retains roughly 3.97 million shares valued at over $73 million.
The mixed analyst sentiment and insider selling could signal uncertainty about Sotera Health's valuation despite its earnings beat. Investors may weigh strong revenue growth and guidance against insider divestment and high leverage. Institutional holders, controlling 91% of shares, could face volatility if retail sentiment shifts. Patients and healthcare providers may be indirectly affected if the company's capital allocation decisions influence its sterilization services pricing or availability.